alogliptin

Contraindicated in:

Type 1 diabetes;
Diabetic ketoacidosis;
Previous severe hypersensitivity reactions.

Use Cautiously in:

Hepatic impairment;
Renal impairment (dose ↓ required if CCr <60 mL/min);
HF or renal impairment (↑ risk for worsening HF);
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children;
Geri: Older adults may have ↑ sensitivity to effects.

Adv. Reactions/Side Effects ⬆ ⬇

CV: HF

Derm: bullous pemphigoid, STEVENS-JOHNSON SYNDROME (SJS)

GI: ↑liver enzymes, HEPATOTOXICITY, PANCREATITIS

MS: arthralgia, RHABDOMYOLYSIS

Neuro: headache

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS OR ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

↑risk of hypoglycemia with sulfonylureas and insulin; dose adjustments may be necessary

Availability ⬆ ⬇

Tablets: 6.25 mg; 12.5 mg; 25 mg
In combination with: metformin (Kazano), pioglitazone (Oseni).

Route/Dosage ⬆ ⬇

PO (Adults ): 25 mg once daily.

Renal Impairment

PO (Adults ): CCr 30–59 mL/min: 12.5 mg once daily; CCr 15–29 mL/min: 6.25 mg once daily; CCr <15 mL/min or requiring hemodialysis: 6.25 mg once daily.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Acts as a competitive inhibitor of dipeptidyl peptidase-4 (DPP-4) which slows the inactivation of incretin hormones, thereby increasing their concentrations and reducing fasting and postprandial glucose concentrations.

Therapeutic effects:

Improved control of blood glucose.

Classifications ⬆ ⬇

Therapeutic Classification: antidiabetics

Pharmacologic Classification: dipeptidyl peptidase-4 dpp-4 inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Completely absorbed following oral administration (100%).

Distribution: Well distributed to tissues.

Metabolism/Excretion: Not extensively metabolized, 76% excreted unchanged in urine.

Half-Life: 21 hr.

Time/Action Profile ⬆ ⬇

(inhibition of DPP-4)

ROUTE	ONSET	PEAK‡	DURATION
PO	unknown	1–2 hr	24 hr

‡Multiple dosing.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take alogliptin as directed. Take missed doses as soon as remembered, unless it is almost time for next dose; do not double dose. Advise patient to read Medication Guide before starting and with each Rx refill in case of changes.
Explain to patient that alogliptin helps control hyperglycemia but does not cure diabetes. Therapy is usually long term.
Instruct patient not to share this medication with others, even if they have the same symptoms; it may harm them.
Encourage patient to follow prescribed diet, medication, and exercise regimen to prevent hyperglycemic or hypoglycemic episodes.
Review signs of hypoglycemia and hyperglycemia with patient. If hypoglycemia occurs, advise patient to take a glass of orange juice or 2–3 tsp of sugar, honey, or corn syrup dissolved in water, and notify health care professional.
Instruct patient in proper testing of blood glucose and urine ketones. These tests should be monitored closely during periods of stress or illness and health care professional notified if significant changes occur.
Advise patient to stop taking alogliptin and notify health care professional promptly if symptoms of hypersensitivity reactions (rash; hives; swelling of face, lips, tongue, and throat; difficulty in breathing or swallowing), liver dysfunction (fatigue, nausea, vomiting, anorexia, right upper abdominal discomfort, dark urine, yellowing of skin or whites of eyes), HF, or pancreatitis occur.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Instruct patient to notify health care professional if severe joint pain occurs.
OB: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

45802- Perrigo New York Inc
- 45802-087- Alogliptin
  - 45802-087-65- 30 TABLET, FILM COATED in 1 BOTTLE (45802-087-65)

45802- Perrigo New York Inc
- 45802-103- Alogliptin
  - 45802-103-65- 30 TABLET, FILM COATED in 1 BOTTLE (45802-103-65)

45802- Perrigo New York Inc
- 45802-150- Alogliptin
  - 45802-150-65- 30 TABLET, FILM COATED in 1 BOTTLE (45802-150-65)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-125- Nesina
  - 64764-125-02- 4 CARTON in 1 TRAY (64764-125-02) > 1 BLISTER PACK in 1 CARTON > 7 TABLET, FILM COATED in 1 BLISTER PACK

64764- Takeda Pharmaceuticals America, Inc.
- 64764-125- Nesina
  - 64764-125-30- 30 TABLET, FILM COATED in 1 BOTTLE (64764-125-30)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-125- Nesina
  - 64764-125-50- 500 TABLET, FILM COATED in 1 BOTTLE (64764-125-50)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-125- Nesina
  - 64764-125-90- 90 TABLET, FILM COATED in 1 BOTTLE (64764-125-90)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-250- Nesina
  - 64764-250-02- 4 CARTON in 1 TRAY (64764-250-02) > 1 BLISTER PACK in 1 CARTON > 7 TABLET, FILM COATED in 1 BLISTER PACK

64764- Takeda Pharmaceuticals America, Inc.
- 64764-250- Nesina
  - 64764-250-30- 30 TABLET, FILM COATED in 1 BOTTLE (64764-250-30)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-250- Nesina
  - 64764-250-50- 500 TABLET, FILM COATED in 1 BOTTLE (64764-250-50)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-250- Nesina
  - 64764-250-90- 90 TABLET, FILM COATED in 1 BOTTLE (64764-250-90)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-625- Nesina
  - 64764-625-30- 30 TABLET, FILM COATED in 1 BOTTLE (64764-625-30)

64764- Takeda Pharmaceuticals America, Inc.
- 64764-625- Nesina
  - 64764-625-90- 90 TABLET, FILM COATED in 1 BOTTLE (64764-625-90)

71610- Aphena Pharma Solutions - Tennessee, LLC
- 71610-300- Alogliptin
  - 71610-300-09- 9000 TABLET, FILM COATED in 1 BOTTLE (71610-300-09)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇